| Identification | Back Directory | [Name]
1-Cyclopentene-1-carboxylic acid, 3-hydroxy- | [CAS]
867178-11-8 | [Synonyms]
HOCPCA
3-Hydroxycyclopent-1-ene-1-carboxylic acid
1-Cyclopentene-1-carboxylic acid, 3-hydroxy- | [Molecular Formula]
C6H8O3 | [MOL File]
867178-11-8.mol | [Molecular Weight]
128.13 |
| Hazard Information | Back Directory | [Uses]
HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability[1]. | [References]
[1] The GHB analogue HOCPCA improves deficits in cognition and sensorimotor function after MCAO via CaMKIIα DOI:10.1177/0271678X231167920 |
|
| Company Name: |
NewCan Biotech Limited
|
| Tel: |
+86-0571-86912261 +86-15658003402 |
| Website: |
https://www.newcanbio.com/ |
|